Does jinyu biological co., ltd. have a prospect?

Jinyu Biotechnology Co., Ltd. (formerly Inner Mongolia Jinyu Group Co., Ltd.) was established in1March 1993 with a registered capital of 572,829,860 yuan, and was listed on the Shanghai Stock Exchange in1October 19991. By the end of September, 20 13, with total capital17.8 billion yuan and 983 employees, it is an excellent listed company in the biopharmaceutical sector of A shares. Jinyu adheres to corporate vision, which is committed to health and creating a better life, and pursues the core values of "people-oriented, flying high", and continues to innovate in management, technology and products, and its core competitiveness is constantly enhanced. Jinyu Ling Bao Biopharmaceutical Co., Ltd. and Yangzhou AIA Biopharmaceutical Co., Ltd. are both state-level high-tech enterprises.

Jinyu Ling Bao Bio-pharmaceutical Co., Ltd. is the vice chairman of China Animal Protection Industry Association, and has the only "National Engineering Laboratory for Veterinary Vaccines" in the industry. In 2008, we overcame the technical difficulties of cell suspension culture and took the lead in launching the first suspension culture production line of foot-and-mouth disease in China, which filled the domestic gap and led the industrial upgrading. 20 12 has established three standards for the industry: antigen content, impurity protein content, antigen and impurity protein detection. Jinyu Biotechnology Industrial Park plans to build a high-standard foot-and-mouth disease suspension culture production line, a brucellosis vaccine production line and a national high-level biosafety laboratory, and take the initiative to undertake the historical mission of promoting product and technology innovation in the domestic biopharmaceutical industry.